Please note that slides are for review only and not to be repurposed or published.

New Agents and Emerging Strategies in the Management of Uterine Sarcomas

Introduction:
Dr Love

MODULE 1:
Clinical Decision-Making for Patients with Localized Uterine Leiomyosarcoma (uLMS) — Dr O’Malley

MODULE 2:
Current Front-Line Management of Metastatic uLMS — Dr Hensley

MODULE 3:
Protocol and Nonresearch Options for Patients with Recurrent/Refractory (R/R) uLMS in Later-Line Settings; Future Directions — Dr George

Beyond the Guidelines: Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer

Introduction:
Dr Love

MODULE 1:
Biologic Rationale for PARP Inhibition in Ovarian Cancer (OC); Current Genetic Testing Algorithms — Dr Coleman

MODULE 2:
Current Role of PARP Inhibition in the Management of Recurrent OC — Dr Liu

MODULE 3:
Unique Tolerability Considerations Associated with PARP Inhibitors — Dr Moore

MODULE 4:
Investigational Applications of Approved PARP Inhibitors; Other Novel PARP Inhibitors in Clinical Development — Dr Mirza

Live Poll Results
Download

Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Ovarian Cancer

Introduction:
Dr Love

MODULE 1:
Local and Systemic Therapeutic Considerations for Patients with Newly Diagnosed Advanced Ovarian Cancer (OC) — Dr Secord

MODULE 2:
Evolving Treatment Paradigms for Patients with Platinum-Sensitive Recurrent OC — Dr Monk

MODULE 3:
Patient- and Disease-Specific Considerations in the Management of Platinum-Resistant Recurrent OC — Dr Dizon

MODULE 4:
Novel Investigational Agents in Development for Patients with OC — Dr Martin

Live Poll Results
Download